Monitor the actual amount raised in the offering (likely much less than maximum given no minimum). Expect continued price pressure toward the $0.75 offering level and further capital raises in coming months. The high short interest and frequent equity issuance pattern suggest persistent bearish sentiment for the common stock.
Price Chart
Executive Summary
Moleculin Biotech is conducting a deeply dilutive 'reasonable best efforts' public offering at $0.75 per share (66% discount to the last $2.19 close), offering up to 11M shares plus 37.1M Series I common warrants (3 warrants per share, exercisable at $0.75). Pro forma shares outstanding would more than double from 7.1M to 18.2M (or 19.5M with pre-funded warrants), and the offering has no minimum, so actual proceeds may be substantially less than the estimated $8.5M net. The company's need for immediate capital and history of frequent equity raises signal severe ongoing dilution with further financing required into early 2027 at best.
Key Facts
- Offering price of $0.75 per share + 3 Series I common warrants (exercise price $0.75, 5-year term) represents ~66% discount to last close of $2.19 on July 27, 2026
- Pro forma shares outstanding immediately after offering: 18,189,047 shares (19,477,380 including pre-funded warrants), up from 7,100,713 pre-offering
- No minimum offering amount; offering may close with substantially less than the maximum $8.5M net proceeds
- Insiders (officers/directors) committed to purchase 1,319,998 shares + 3,959,994 common warrants on same terms
- Issuance likely triggers anti-dilution adjustments on existing Series G/H warrants (floor prices $1.326/$0.962), potentially reducing their exercise prices and adding future dilution
- Company had 24 offering/registration filings in the last 24 months; short interest ~19.8% of estimated shares outstanding as of July 15, 2026
- Net tangible book value per share declines from $0.76 to $0.71 after offering per filing (immediate dilution of $0.04 per share to new investors)
Financial Impact
Up to $8.5M net proceeds (if fully sold) on a $2M market cap, but massive dilution of ~156% in share count; potential additional dilution from 37.1M common warrants and anti-dilution adjustments on existing warrants
Risk Factors
- Extreme dilution from this offering plus potential exercise of 37.1M common warrants and anti-dilution repricing of existing warrants
- No minimum offering amount means the company may raise insufficient capital to fund operations, increasing need for additional (dilutive) financing
- Clinical-stage biotech with no approved products; Phase 2/3 MIRACLE trial interim data not yet statistically significant
- Historical non-compliance with Nasdaq listing rules (bid price and equity rules) increases delisting risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-025335 |
| Document: 0001437749-26-025335-index-headers.html | 0001437749-26-025335 |
| Document: 0001437749-26-025335-index.html | 0001437749-26-025335 |
| Document: 0001437749-26-025335.txt | 0001437749-26-025335 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers